Partnership aims to address United Nations Sustainable Development Goal 3.1
ROCKVILLE, Md., July 19, 2022 /CNW/ — Inteleos™, a non-profit global healthcare certification organization, and the Kenya Women and Children’s Wellness Center (KWCWC) signed a memorandum of understanding to reduce maternal and fetal morbidity and mortality in Kenya by providing comprehensive ultrasound training and certification programs that match Kenyan clinical practices and resources for nurses, midwives and clinical officers.
The joint effort aligns with United Nations Sustainable Development Goal 3.1, to reduce the global maternal mortality ratio to less than 70 per 100,000 live births by 2030.
Training will include knowledge checks and assessment exams that culminate in globally recognized ultrasound certifications.
The partnership will provide Kenyan women with critical information about their overall health and pregnancy progress and ensure that both the expectant mother and unborn baby receive the best pathway of care available. Additionally, the program supports a predominately female workforce by providing education and validating proficiency in ultrasound knowledge skills and abilities, empowering female providers and patients, and strengthening nursing and midwifery leadership. Inteleos and KWCWC will provide necessary staffing and resources to support the program.
“Through active listening, learning and collaboration with the Kenya Women and Children’s Wellness Center and broader East African healthcare systems, Inteleos provides positive transformational impact through our specific expertise in diagnostic ultrasound assessment and certification,” said Pamela Ruiz, Chief Business Development Officer of Inteleos.
“We couldn’t be more proud to partner with Inteleos to deliver the necessary tools, training and assessments to our nurses, midwives and clinical officers with the goal of providing best practices in diagnostic medical imaging to reduce maternal and fetal mortality,” said Faith Muigai, executive director of KWCWC. “This partnership supports KWCWC goal to expand our reach and drive impact to empower disenfranchised communities by prioritizing science and technology that provides meaningful interventions that strengthen the Pan-African ecosystem.”
As of 2017 in Kenya, 342 women died per 100,000 live births. Inteleos and KWCWC have a unique opportunity to reduce maternal and fetal morbidity and mortality in Kenya and other areas of Sub-Saharan Africa with appropriate use of diagnostic ultrasound in the hands of proficient nurses, midwives and clinical officers. The Kenya Women and Children’s Wellness Centre (KWCWC) located on the campus of the United States International University in Nairobi Kenya, and housed on 10 acres of dedicated land, is a state-of-the-art healthcare facility whose programming shares a common intent to serve the health and wellness of the Kasarani community.
Inteleos™ is a non-profit certification organization that delivers rigorous assessments and cultivates a global community of professionals dedicated to the highest standards in healthcare and patient safety. Inteleos is the overarching governance and management organization for the American Registry for Diagnostic Medical Sonography® (ARDMS®) the Alliance for Physician Certification & Advancement™ (APCA™) and the Point-of-Care Ultrasound Certification Academy™ (POCUS™) which together represents over 124,000 certified medical professionals throughout the world. The Inteleos Foundation represents the philanthropic efforts for the organization.
View original content:https://www.prnewswire.com/news-releases/inteleos-and-kenya-women-and-childrens-wellness-center-partner-to-reduce-maternal-and-fetal-mortality-301589182.html
View original content: http://www.newswire.ca/en/releases/archive/July2022/19/c6538.html
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
Between the Fed's aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among investors, others view market volatility as a unique buying opportunity. Opportunity is the key word – and sometimes the hardest thing for investors to see. To find names that can deliver solid returns and now come with a bargain price tag, investors will often tur
Apple Inc on Wednesday released a report outlining a two-pronged strategy in digital health markets, courting consumers with health and fitness features on one hand while engaging with traditional healthcare systems on the other. Spearheaded by Apple's chief operating officer, Jeff Williams, the report is the first time Apple has offered a comprehensive view of its approach to healthcare markets in the eight years since it began releasing health features such as a medical records storage system on iPhones. It has also started partnering with institutions such the Stanford University School of Medicine to conduct large-scale formal medical studies.
Is Johnson & Johnson stock a sell after cutting its 2022 outlook amid currency concerns? Is JNJ stock a sell right now?
IT prioritizes access and inclusion for employees with disabilities
The U.S. Centers for Disease Control and Prevention authorized the Novavax vaccine for adults late Tuesday, clearing the final obstacle to the use of a fourth alternative and one that is based on more traditional technology than earlier shots.
The burrito chain cited staffing problems at the Augusta store; a lawyer for organizers said the company is worried about the growing unionization effort.
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phase 1 study will examine the PK in patients with moderate renal and hepatic impairment. Using a cross-over design, two doses of STI-1558 (300 mg and 600 mg) will be studied in 12 subjects across three cohorts. Related: FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron. Th
ABC News’ Linsey Davis spoke with directors and producers Tonya Lewis Lee and Paula Eiselt about the growing Black maternity health crisis in their new documentary “Aftershock.”
Carlos Cope, 24, was found guilty of rape and assault after a week-long trial and sentenced at Warwick Crown Court.
(Reuters) -Biogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm. Biogen also disclosed that it had agreed to pay $900 million to resolve a whistleblower lawsuit accusing it of paying doctors kickbacks to prescribe multiple sclerosis drugs. Biogen's experimental Alzheimer's drug, lecanemab, is crucial for the growth of the drugmaker as it faces competition for several of its blockbuster drugs, including multiple sclerosis treatment Tecfidera.
“I told Emily that if I had to crawl to the North Pole, I would, if that’s what it took to find someone to fix her,” says dad, Tom Whitehead.
Pakistan's police have arrested at least two people after a 21-year-old American woman reported she was gang raped at a hotel when she was visiting a tourist resort in the eastern Punjab province, officials said Wednesday. The detainees included the woman's host, who took her to a hotel in Dera Ghazi Khan, a district in the Punjab province where she says she was sexually assaulted this week, according to an initial police investigation. The U.S. Embassy in Islamabad told The Associated Press that its consulate in Pakistan's city of Lahore was ready to provide consular services to the victim.
Johnston County met with community members Tuesday. Wake County meets soon. On the table? Millions for local programs from the national settlement with opioid manufacturers and distributors.
By Shelley D. Harper
The CDC approved Novavax's COVID vaccine on Tuesday, and investors sent Novavax's stock up 11.5%
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
A resident of a newly built apartment building in South Korea began noticing an odor coming from their master bedroom’s closet that became increasingly worse, later discovering three bags of human feces hidden inside a space in the ceiling. The apartment building, located in Hwaseong, Gyeonggi province, had only recently been built. As new residents began to move in, one noticed a “strong stench” coming from the walls of the master bedroom’s closet.
IBD Stock Of The Day Incyte just won U.S. approval for a new skin treatment, leading Incyte stock to flirt with a breakout.
‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort